LCK: Tyrosine-protein kinase Lck
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on LCK, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| PazopanibBoxed warning | Approved | Novartis Pharmaceuticals | Small molecule | InhibitorTyrosine-protein kinase LCK inhibitor | 27 |
| JNJ-26483327 | Phase 1 | Johnson & Johnson | Small molecule | InhibitorTyrosine-protein kinase LCK inhibitor | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Severe combined immunodeficiency due to LCK deficiency
- 0.76
- Cancer
- 0.59
- Sarcoma
- 0.50
- Neoplasm
- 0.50
- HIV infectious disease
- 0.46
- Combined immunodeficiency
- 0.46
Genes and related targets
Complexes and families that share a gene with this target- Genes
- LCK
- Related
- SRC
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL258, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P06239, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets